Adoptive immunotherapy of cancer with immune and activated lymphocytes: Experimental and clinical studies

Giorgio Parmiani, Maria Luisa Sensi, Andrea Balsari, Mario P. Colombo, Carlo Gambacorti-Passerini, Laura Grazioli, Monica Rodolfo, Natale Cascinelli, Giuseppe Fossati

Research output: Contribution to journalArticle

Abstract

Recent studies of passive adoptive immunotherapy of experimental tumors indicate that histologically different neoplasms can be cured by this procedure in mice, rats and guinea pigs. In this paper two main approaches of adoptive immunotherapy with lymphocytes are considered. One which makes use of specific tumor-immune cells and is applicable to immunogenic tumors, and the other which uses activated (allostimulated and/or IL-2-activated) lymphocytes and is applicable to immunogenic and non-immunogenic neoplasms. Experimental models of both approaches and results provided by them are reviewed. These studies indicate that transfer of tumor-reactive lymphocytes with or without the combined administration of IL-2 into syngeneic tumor-bearing animals can lead to the eradication of a disseminated neoplasia when certain conditions are met. In particular, it was found that high tumor burdens, delay of treatment and low number of transferred lymphocytes can adversely affect the results. It has also been shown that the therapeutic effect of treatment with anti-cancer drugs or irradiation may be significantly improved by the addition of adoptive immunotherapy. The successful treatment of immunogenic tumors often requires the inhibition of suppressor lymphocytes by Cy or irradiation. Non-immunogenic tumors can be successfully treated only by providing activated lymphocytes and high doses of IL-2. Recent findings of few available human studies of adoptive immunotherapy are also reviewed, and the problems of toxicity and possible therapeutic effects of infusion of autologous, activated lymphocytes and IL-2 are discussed.

Original languageEnglish
Pages (from-to)1-20
Number of pages20
JournalLa Ricerca in Clinica e in Laboratorio
Volume16
Issue number1
DOIs
Publication statusPublished - Jan 1986

Fingerprint

Adoptive Immunotherapy
Lymphocytes
Tumors
Interleukin-2
Neoplasms
Bearings (structural)
Therapeutic Uses
Irradiation
Clinical Studies
Toxicity
Passive Immunization
Rats
Animals
Lymphocyte Count
Tumor Burden
Guinea Pigs
Theoretical Models
Therapeutics

Keywords

  • Allostimulation
  • Immunotherapy
  • Interleukin-2
  • Lymphocytes
  • Mouse and human tumors

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Adoptive immunotherapy of cancer with immune and activated lymphocytes : Experimental and clinical studies. / Parmiani, Giorgio; Sensi, Maria Luisa; Balsari, Andrea; Colombo, Mario P.; Gambacorti-Passerini, Carlo; Grazioli, Laura; Rodolfo, Monica; Cascinelli, Natale; Fossati, Giuseppe.

In: La Ricerca in Clinica e in Laboratorio, Vol. 16, No. 1, 01.1986, p. 1-20.

Research output: Contribution to journalArticle

Parmiani, Giorgio ; Sensi, Maria Luisa ; Balsari, Andrea ; Colombo, Mario P. ; Gambacorti-Passerini, Carlo ; Grazioli, Laura ; Rodolfo, Monica ; Cascinelli, Natale ; Fossati, Giuseppe. / Adoptive immunotherapy of cancer with immune and activated lymphocytes : Experimental and clinical studies. In: La Ricerca in Clinica e in Laboratorio. 1986 ; Vol. 16, No. 1. pp. 1-20.
@article{f5b03560c8a24b7f87fa49f91b741e78,
title = "Adoptive immunotherapy of cancer with immune and activated lymphocytes: Experimental and clinical studies",
abstract = "Recent studies of passive adoptive immunotherapy of experimental tumors indicate that histologically different neoplasms can be cured by this procedure in mice, rats and guinea pigs. In this paper two main approaches of adoptive immunotherapy with lymphocytes are considered. One which makes use of specific tumor-immune cells and is applicable to immunogenic tumors, and the other which uses activated (allostimulated and/or IL-2-activated) lymphocytes and is applicable to immunogenic and non-immunogenic neoplasms. Experimental models of both approaches and results provided by them are reviewed. These studies indicate that transfer of tumor-reactive lymphocytes with or without the combined administration of IL-2 into syngeneic tumor-bearing animals can lead to the eradication of a disseminated neoplasia when certain conditions are met. In particular, it was found that high tumor burdens, delay of treatment and low number of transferred lymphocytes can adversely affect the results. It has also been shown that the therapeutic effect of treatment with anti-cancer drugs or irradiation may be significantly improved by the addition of adoptive immunotherapy. The successful treatment of immunogenic tumors often requires the inhibition of suppressor lymphocytes by Cy or irradiation. Non-immunogenic tumors can be successfully treated only by providing activated lymphocytes and high doses of IL-2. Recent findings of few available human studies of adoptive immunotherapy are also reviewed, and the problems of toxicity and possible therapeutic effects of infusion of autologous, activated lymphocytes and IL-2 are discussed.",
keywords = "Allostimulation, Immunotherapy, Interleukin-2, Lymphocytes, Mouse and human tumors",
author = "Giorgio Parmiani and Sensi, {Maria Luisa} and Andrea Balsari and Colombo, {Mario P.} and Carlo Gambacorti-Passerini and Laura Grazioli and Monica Rodolfo and Natale Cascinelli and Giuseppe Fossati",
year = "1986",
month = "1",
doi = "10.1007/BF02886719",
language = "English",
volume = "16",
pages = "1--20",
journal = "Ricerca in Clinica e in Laboratorio",
issn = "0940-5437",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Adoptive immunotherapy of cancer with immune and activated lymphocytes

T2 - Experimental and clinical studies

AU - Parmiani, Giorgio

AU - Sensi, Maria Luisa

AU - Balsari, Andrea

AU - Colombo, Mario P.

AU - Gambacorti-Passerini, Carlo

AU - Grazioli, Laura

AU - Rodolfo, Monica

AU - Cascinelli, Natale

AU - Fossati, Giuseppe

PY - 1986/1

Y1 - 1986/1

N2 - Recent studies of passive adoptive immunotherapy of experimental tumors indicate that histologically different neoplasms can be cured by this procedure in mice, rats and guinea pigs. In this paper two main approaches of adoptive immunotherapy with lymphocytes are considered. One which makes use of specific tumor-immune cells and is applicable to immunogenic tumors, and the other which uses activated (allostimulated and/or IL-2-activated) lymphocytes and is applicable to immunogenic and non-immunogenic neoplasms. Experimental models of both approaches and results provided by them are reviewed. These studies indicate that transfer of tumor-reactive lymphocytes with or without the combined administration of IL-2 into syngeneic tumor-bearing animals can lead to the eradication of a disseminated neoplasia when certain conditions are met. In particular, it was found that high tumor burdens, delay of treatment and low number of transferred lymphocytes can adversely affect the results. It has also been shown that the therapeutic effect of treatment with anti-cancer drugs or irradiation may be significantly improved by the addition of adoptive immunotherapy. The successful treatment of immunogenic tumors often requires the inhibition of suppressor lymphocytes by Cy or irradiation. Non-immunogenic tumors can be successfully treated only by providing activated lymphocytes and high doses of IL-2. Recent findings of few available human studies of adoptive immunotherapy are also reviewed, and the problems of toxicity and possible therapeutic effects of infusion of autologous, activated lymphocytes and IL-2 are discussed.

AB - Recent studies of passive adoptive immunotherapy of experimental tumors indicate that histologically different neoplasms can be cured by this procedure in mice, rats and guinea pigs. In this paper two main approaches of adoptive immunotherapy with lymphocytes are considered. One which makes use of specific tumor-immune cells and is applicable to immunogenic tumors, and the other which uses activated (allostimulated and/or IL-2-activated) lymphocytes and is applicable to immunogenic and non-immunogenic neoplasms. Experimental models of both approaches and results provided by them are reviewed. These studies indicate that transfer of tumor-reactive lymphocytes with or without the combined administration of IL-2 into syngeneic tumor-bearing animals can lead to the eradication of a disseminated neoplasia when certain conditions are met. In particular, it was found that high tumor burdens, delay of treatment and low number of transferred lymphocytes can adversely affect the results. It has also been shown that the therapeutic effect of treatment with anti-cancer drugs or irradiation may be significantly improved by the addition of adoptive immunotherapy. The successful treatment of immunogenic tumors often requires the inhibition of suppressor lymphocytes by Cy or irradiation. Non-immunogenic tumors can be successfully treated only by providing activated lymphocytes and high doses of IL-2. Recent findings of few available human studies of adoptive immunotherapy are also reviewed, and the problems of toxicity and possible therapeutic effects of infusion of autologous, activated lymphocytes and IL-2 are discussed.

KW - Allostimulation

KW - Immunotherapy

KW - Interleukin-2

KW - Lymphocytes

KW - Mouse and human tumors

UR - http://www.scopus.com/inward/record.url?scp=0022449136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022449136&partnerID=8YFLogxK

U2 - 10.1007/BF02886719

DO - 10.1007/BF02886719

M3 - Article

C2 - 2874605

AN - SCOPUS:0022449136

VL - 16

SP - 1

EP - 20

JO - Ricerca in Clinica e in Laboratorio

JF - Ricerca in Clinica e in Laboratorio

SN - 0940-5437

IS - 1

ER -